Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Single Ascending Dose Study of HM17321 in Healthy Adult Participants
Sponsor: Hanmi Pharmaceutical Company Limited
Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single ascending doses in healthy adult participants.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-11-06
Completion Date
2026-04
Last Updated
2026-02-25
Healthy Volunteers
Yes
Interventions
HM17321
Participants will receive a single subcutaneous injection of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.
Placebo of HM17321
Participants will receive a single subcutaneous injection of a matching placebo solution in prefilled syringes. The placebo does not contain any active ingredients.
Locations (1)
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States